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Background: Fat embolization (FE) and the consequent fat embolism syndrome (FES) remain 
poorly understood complications of skeletal and other major trauma. While FE and FES can lead 
to major pulmonary damage including ARDS and death, current treatment of FES is limited to 
supportive therapy. The renin angiotensin system (RAS) plays a significant role in the 
pathophysiology of FE, and drugs interfering with the RAS, captopril and losartan, have reduced 
histopathologic pulmonary damage in a rat model of FE. In this study, we examine the potential 
therapeutic effects of aliskiren, a direct renin inhibitor, on lung histopathology following FE.  
Methods: A model of FE was created in unanesthetized rats using intravenous injection of the 
neutral fat triolein. Intraperitoneal injections of aliskiren at either 50 mg/kg or 100 mg/kg were 
performed one hour after FE induction via triolein. Rats were euthanized at 48 hours, and various 
pathology stains and methods were used to study and compare the lungs of these animals.  
Results: The lungs of the triolein only treated animals showed severe gross and histopathologic 
damage which was mitigated by aliskiren. (1) Fibrosis: Rats treated with triolein alone showed 
significant fibrotic changes with increased collagen and myofibroblast activation (p < 0.01). 
Aliskiren blocked this inflammatory and profibrotic process to a level indistinguishable from the 
controls (p < 0.01). (2) Fat: Rats treated with triolein alone showed a statistically significant 
increase in fat (p < 0.01) with subsequent aliskiren administration at both doses reducing the 
size, distribution, and amount of fat droplets (p<0.01). (3) Vasculitis: There was a trend in 





Conclusions: Aliskiren protected the lungs of these rats from FE-induced pulmonary damage at 
48 hours. Clinical implications include the use of aliskiren both prophylactically (before certain 
orthopedic procedures) and therapeutically (after severe trauma) to prevent the consequent 
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Definitions and Relevance   
Fat embolism (FE) is the presence of fat globules in the peripheral circulation and lung 
parenchyma and is primarily subclincal. Fat embolism syndrome (FES) is a serious consequence 
of FE, typically manifesting as distinct triad of pulmonary, dermatologic, and neurologic 
dysfunction. While majority (95%) of FES cases develop following major orthopedic trauma1, a 
multitude of less common risk factors include orthopedic procedures, extensive burns, bone 
marrow harvest, diabetes mellitus, pancreatitis, liposuction, sickle cell crisis, alcoholic liver 
disease, and other soft tissue injury.2 
FE leads to either negligible lung injury or, less frequently, to a cascade of events 
presenting as FES and serious acute respiratory distress syndrome (ARDS). While it was 
previously believed that there are no long-term pulmonary sequelae after subclinical FE or even 
clinical FES, it has recently been reported in a follow-up study on 5-year outcomes that survivors 
of ARDS do not return to normal predicted levels of physiological function.3 In addition, the 
lungs of animals exposed to FE demonstrate severe pulmonary fibrosis and heightened 
vulnerability to further exposure of an insult.4 Thus, while FE might not initially produce 
clinically obvious respiratory problems, there may be a silent inflammatory and fibrotic process 
occurring with harmful implications later in life such as contribution to the development of 
idiopathic pulmonary fibrosis. 
Incidence and Mortality  
FE has been estimated to occur in more than 90% of patients with traumatic injury.5 
Further confirmation of this high incidence figure came from a recent autopsy series reporting fat 
emboli in the pulmonary circulation of 82% of trauma patient.6 FES has a wide range of 
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incidence rates in current orthopedic and trauma literature ranging from as low as 0.2-0.9% in 
retrospective studies and as high as 35% in prospective studies.1 The great variability in 
incidence rates can be accounted for by the heterogeneity of diagnostic criteria, inconsistent 
clinical recognition, or overshadowing by other illnesses or injuries. Mortality figures are also 
discrepant with an overall mortality rate ranging from 2.5-20% as recently described in the 
current literature.1 If FE is a risk factor for later development of IPF as we have proposed from 
suggestive findings, broader implications related to the burden of IPF include the 200,000 people 
in the US7, 8 with IPF contributing to 40,000 deaths each year and an estimated annual IPF-
attributable medical cost of $2 billion to the U.S. health care system.9 
Treatment 
To date, there are no pharmacologic therapies for the prevention or treatment of FES, 
which may contribute to the high mortality rates. Current treatment of FES is limited to 
supportive care including respiratory support (oxygen, mechanical ventilation), volume 
replacement for hemodynamic stability (fluids, blood products), and analgesia.10 Therapies such 
as heparin and corticosteroids11-15  have been employed in humans, however, neither have 
reliably been proven to improve morbidity and mortality. 
Experimental Models of FE 
Since it is generally not feasible to study the pathophysiology of FE and FES in humans, 
much of our understanding is based on systematic experimentation in animals. The diversity of 
animal models of FE to simulate that of humans is broad including the displacement of the 
animals’ bone marrow fat into circulation or direct, intravenous injection of a mimicking 
substance (neutral fats, fatty acids, or the animal’s own subcutaneous fat).9, 16-19 Our model of FE 
developed and employed in past studies4, 20-22 and the current study has several advantages. First, 
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we use the neutral fat triolein, the predominant fat bone marrow,23 rather than oleic acid, a toxic 
fatty acid thought to be produced by lipases in the lung.24, 25 Second, the rats are conscious 
during the intravenous injections of triolein, avoiding the complications of anesthesia on 
respiratory function.26 Third, the experiments are carried out at 48 hours post-triolein injection 
based on our previous studies demonstrating peak histopathological effects at this time point.20  
Lastly, the same histopathological pulmonary damage as demonstrated in our animal model has 
been found in FES studied in human autopsies, strengthening the confidence for application to 
humans.27 
Proposed pathophysiology  
The renin-angiotensin system (RAS) has been implicated in the pathophysiology of FE, 
notably through the pro-fibrotic properties of Angiotensin II (Ang II).28 Inhibition of RAS 
through various mechanisms has proved to be a successful strategy for mitigating the 
histopathologic damage after FE.21 The protective effects of an angiotensin-converting enzyme 
(ACE) inhibitor, captopril, and an Ang II type I receptor blocker, losartan, underlined the 
involvement of Ang II and the Ang II type I receptor. However, since these past results did not 
indicate 100% blockade of FE-induced pathology, there is uncertainty whether this Ang II is 
solely a product of ACE or if there is involvement of another enzyme such as Ang II- forming 
chymase acting on angiotensin I (Ang I).29 In addition, an increase in renin has been 
demonstrated in the lungs30 and kidneys31 post-triolein injection, justifying the attempt to block 
renin as a mediator. 
As an extension of our previous findings, we have employed the use of aliskiren, a direct 
renin inhibitor, in our FE model in rats. The use of aliskiren allows us to examine the effect of 
directly inhibiting the rate limiting enzyme, renin, in Ang I and ultimately Ang II production. In 
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this study, we investigate the effects of aliskiren on lung histopathology following triolein-
induced FE to further elucidate the roles these various RAS mediators play in the pathogenesis of 
FE.  
Materials and Methods  
Responsible Conduct of Research  
This study was conducted under the approval of the University of Missouri at Kansas 
City Institutional Animal Care and Use Committee (IACUC), Protocol # 1507. Animal care and 
procedures were in accordance with institutional guidelines. 
Animals and Experimental Design  
Following approval of the protocol, we obtained a total of 22 male Sprague-Dawley rats 
(280-300 g) from Harlan Laboratories (Indianapolis, IN) and divided them into four groups as 
presented in table 1. Pure triolein (glyceryl trioleate, Sigma grade; Sigma Corp., St. Louis, MO) 
was used to simulate a FE. Group A (n=4) controls received 0.2 mL intravenous (i.v.) normal 
saline (NS) at 0 hours and 0.2 mL intraperitoneal (i.p.) NS at hour 1. Group B (n=6) received 
pure triolein 0.2 mL i.v. at 0 hours and NS 0.2 mL i.p at hour 1. Group C (n=6) received the 
same dose of triolein at 0 hours and aliskiren 50 mg/kg at hour 1. Group D (n=6) received the 
same dose of triolein at 0 hours and aliskiren 100 mg/kg at hour 1.  
The dose of triolein was selected based on our previous work with unanesthetized rats4, 20-
22 which demonstrated this dose to induce very severe pathologic changes coupled with a low 
incidence of mortality. The doses of aliskiren have been used in rats in published experiments at 
different time periods: 50 mg/kg i.p. daily for up to 8 weeks32 and 100 mg/kg i.p. for only 60 
minutes.33 While aliskiren is orally active, we chose intraperitoneal injections of aliskiren for this 
study rather than oral administration to mimic our previous experiments. Intraperitoneal 
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administration avoids potential aspiration which would complicate our findings and the validity 
of our results when studying pulmonary histopathology. Similar to the previous experiment with 
captopril and losartan,21 aliskiren was used as a rescue drug 1 hour after the initial insult of 
triolein injection, more closely simulating the most common risk factor for FE, trauma. All rats 
were given libitum access to food and water, and clinical observations were made at various time 
points before and after the injections. No animals died early, and all 22 rats were euthanized at 
48 hours using inhalation isoflurane.  
 
Group n Day 0 
Time 0 hours 
Day 0 
Time 1 hour 
Day 2   
Time 48 hours 
A 4 Saline 0.2 mL i.v. Saline 0.2 mL i.p. Euthanasia 
B 6 Triolein 0.2 mL i.v. Saline 0.2 mL i.p. Euthanasia 
C 6 Triolein 0.2 mL i.v. Aliskiren 50 mg/kg i.p. Euthanasia 
D 6 Triolein 0.2 mL i.v. Aliskiren 100 mg/kg i.p. Euthanasia 
Table 1. Treatment Groups 
 
Pathology Procedures  
After euthanasia, rats were necropsied, and the viscera of the thoracic and abdominal 
cavity were removed and inspected for gross anatomic pathologic changes. The lower lobe of the 
right lungs were collected and placed in 10% buffered formalin solution for fixation. After 10 
days of fixation, the specimens were paraffin embedded, cut in sagittal sections (4 µm), and 
stained with hematoxylin and eosin (H&E) for histological evaluation and vessel measurements. 
Slides were also stained with Masson’s trichrome (trichrome) for collagen identification. 
Immunolabeling of lung alpha-smooth muscle actin (α-SMA) as a marker for myofibroblasts 
activation and differentiation was performed using previously described protocols.34 The lower 
lobe of the left lungs were frozen at -20°C, sectioned, and stained for fat using Oil Red O. 
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 Histologic evaluation was performed by two researchers who were blinded to the slide 
identity. Histopathologic studies were done on slides stained for H&E, trichrome, α-SMA, and 
Oil Red O.  Ten photographs of each H&E slide were taken at 400x magnification. From these 
photographs, the lumen patency and media to adventitia ratio of at least five small caliber 
pulmonary arteries and arterioles were measured per slide. The lumen patency of these vessels 
were evaluated by measuring the luminal diameter divided by the external diameter of the vessel 
media. The media-to-adventitia ratio of these vessels were evaluated by measuring the external 
diameter of the media divided by the external diameter of the adventitia. Figure 1 shows the 
graphic representation. Eight photographs of each Oil Red O stained slide were taken at 100x 
magnification, ten photographs of each trichrome stained slide were taken at 400x magnification, 
and ten photographs of each α-SMA stained slide were taken at 400x magnification. The slides 
stained with Oil Red O, trichrome, and α-SMA were then digitally analyzed using the Image J 
Software (NIH) to quantify the amount of fat, collagen, and myofibroblasts present in each slide, 
respectively. See figure 2 for Image J demonstration.  
Statistical Analysis  
Data was statistically analyzed using analyses of variance, and, where appropriate, 
comparisons were made using Fisher’s least significant differences. The level of statistical 
significance for comparison was set at p=0.01. The data analysis for this study was generated 





Figure 1. Graphic representation of the lumen patency and media-to-adventitia ratio measurements.  
 Lumen Patency= (A+B)/(C+D) 
 Media-to-adventitia ratio= (C+D)/(E+F) 
 
 
Figure 2. Graphic representation of Image J analysis of a trichrome-stained slide. The Image J software is capturing 




All rats survived the injections. The rats injected with triolein became hypoactive 
immediately following the injections, but regained activity within a couple of hours and were 
indistinguishable from the controls as seen in our past studies.4, 20-22 On days 1 and 2, the rats 
continued to show no apparent signs of distress.   
Gross Organ Appearance at Necropsy 
The gross organ anatomy of the controls showed clean surfaces of the lungs with no 
pathology. Multiple organs of the triolein-injected rats in group B displayed gross pathologic 
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changes: liver congestion evidenced by a dark, speckled appearance; cardiovascular changes 
including right ventricular and inferior vena cava dilatation; and congestion and enlargement of 
the spleen. The lungs exhibited severe congestion as evidenced by diffuse pleural hemorrhages 
and cobblestoning of the pleural surface. The animals treated with aliskiren in groups C and D 
showed less pulmonary pathology with smooth pleural surfaces, minimal if any pleural 
hemorrhages, and less organ congestion. Two unique findings included an animal in group C 
with left renal deposits representing possible inflammation or calcification, and an animal in 
group D with notable ascites and organ pathology similar to the triolein-only treated animals.  
Pulmonary Histopathology (H&E Staining) 
Representative H&E stained slides from the four different treatment groups are presented 
in figure 3. Rats of the control group demonstrated patent small caliber arteries and arterioles 
with appropriately few inflammatory cells throughout pulmonary parenchyma. Histologic 
findings in the triolein-only treated animals, group B, mirrored that of past studies, confirming 
the reproduction of our FE model. Numerous signs of pathology were present in these animals: 
diffuse hemorrhages present in the thickened septa; congestion and diffuse inflammation 
comprised of neutrophils, lymphocytes, macrophages, and erythrocytes; and scattered areas of 
atelectasis and emphysema. Bronchial changes included thickening of the bronchial musculature, 
epithelial hypertrophy and inflammation, variable areas of disepithelialization, and loss of cilia. 
The lumen of large bronchi were also filled with edematous fluid, erythrocytes, and 
inflammatory cells. The small arteries and arterioles showed signs of severe vasculitis: thickened 
media, reduced luminal patency, and periadventitial edema. Some of these changes were present, 
but less severe, in the rats treated with aliskiren. Quantification of lumen patency and media-to-
adventitia ratios are depicted in Figure 4. In the triolein- only treated animals, there was a trend 
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in reduced lumen patency compared to the controls, albeit not statistically significant, 
representing the vasculitis and media hypertrophy resulting after triolein injection (p=0.0641). 
Improvement in the aliskiren-treated animals was evidenced by increased lumen patency in the 
aliskiren 50 mg/kg group (p=0.0058), without statistical significance among the aliskiren 100 
mg/kg group (p=0.1134). No difference was observed in the media-to-adventitia ratios among 
treatment groups.  
 
Figure 3. Representative hematoxylin and eosin (H&E) stained slides from the lungs of the four different treatment 
groups: saline + saline controls (A), triolein + saline (B), triolein + aliskiren 50 mg/kg (C), and triolein + aliskiren 
100 mg/kg (D). Photographed at 400x. The triolein only group (B) demonstrated marked thickening of the arterial 
walls with severe septal inflammation. The histopathology improved with increased lumen patency of the arteries 





Figure 4. Effects of aliskiren on triolein-induced arterial lumen patency (A) and media-to-adventitia ratio (B). 
Asterisks indicate a significant difference from the triolein group, p<0.01. While there is a trend of decreased lumen 
patency in the triolein-only group with respect to the controls, the number of vessels evaluated only allowed for 
detection of a significant difference between the two indicated treatment groups. No difference was observed in the 
media-to-adventitia ratios. 
 
Pulmonary Histopathology (Trichrome and α-SMA Staining) 
Representative trichrome and α-SMA stained slides from the four different treatment 
groups are presented in figures 5 and 6. In the triolein-only treated animals, trichrome staining 
showed collagen diffusely present in the parenchyma, media and adventitia of small-caliber 
arteries and arterioles, peribronchial musculature, and subpleural regions. The location and 
distribution of α-SMA expression in myofibroblasts closely paralleled that of the collagen.  
However, α-SMA staining was more intense and diffusely present in the intraseptal and 
perivascular areas. α-SMA expression and fibrosis were significantly reduced in both groups of 
the aliskiren-treated animals. Quantification of trichrome and α-SMA content by Image J 
confirmed that rats treated with triolein alone, group B, showed statistically significant fibrotic 
changes with increased collagen (Masson’s trichrome) and myofibroblast activation (α-SMA) 
compared to the others three groups (p < 0.01) as seen in figures 7 and 8. Aliskiren blocked this 
inflammatory and fibrotic process by reducing the intensity of these stains to a level 
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indistinguishable from the controls (p < 0.01). Thus, there was no detectable difference in 
collagen or α-SMA expression between the controls and aliskiren treated animals at both doses.  
 
 
Figure 5. Representative trichrome-stained slides from the lungs of the four different treatment groups: saline + 
saline controls (A), triolein + saline (B), triolein + aliskiren 50 mg/kg (C), and triolein + aliskiren 100 mg/kg (D). 
Photographed at 400x. Collagen is stained blue. The triolein only group (B) demonstrates a severe inflammatory and 
fibrotic response evidenced by the increased collagen deposition in the perivascular and interstitial space. This 
response was blocked in the aliskiren-treated animals which displayed limited collagen mainly confined to the 





Figure 6. Representative alpha smooth muscle actin  (α-SMA) stained slides from the lungs of the four different 
treatment groups: saline + saline controls (A), triolein + saline (B), triolein + aliskiren 50 mg/kg (C), and triolein + 
aliskiren 100 mg/kg (D). Photographed at 400x. Immunolabeling for α-SMA is represented in yellow-brown 
staining as a marker of myofibroblast activation and differentiation. Similar to the trichrome stain, the triolein only 







Figure 7. Image J analysis of the intensity of trichrome staining of rat lungs subjected to different treatments. 
Asterisks indicate significant difference from the triolein group, p<0.01. 
 
 
Figure 8. Image J analysis of the intensity of α- SMA staining of rat lungs subjected to different treatments. 
Asterisks indicate significant difference from the triolein group, p<0.01.  
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Fat Distribution in Lungs (Oil Red O Staining) 
Representative Oil Red O stained slides from the four different treatment groups are presented in 
figure 9. Saline injected controls had a minimal amount of fat present while the lungs of the 
triolein-only treated animals had a larger amount of fat which was present as small droplets 
diffuse throughout the pulmonary interstitial space or as large droplets around peribronchial 
veins; both groups confirm findings of our previous studies conducted at the same interval of 
time.20, 21 Fat droplets present in the rats treated with aliskiren were comparatively small in size 
and mostly located around peribronchial veins, traversing the vascular musculature. Few droplets 
were present throughout the alveolar septa. Rats treated with triolein alone, group B, showed a 
statistically significant increase in fat compared to the others three groups (p < 0.01). Aliskiren 
administration at both doses reduced the presence of fat to a level indistinguishable from the 
controls. (Figure 10). Thus, while a large amount of fat is present in the rat lungs after triolein 
administration, subsequent treatment with aliskiren results in a decreased amount of fat to a level 




Figure 9. Representative Oil Red O stained slides from the lungs of the four different treatment groups: saline + 
saline controls (A), triolein + saline (B), triolein + aliskiren 50 mg/kg (C), and triolein + aliskiren 100 mg/kg (D). 
Photographed at 100x. Fat is stained red. The triolein only group demonstrated large fat globules diffuse through the 
pulmonary parenchyma. Aliskiren treatment resulted in comparatively smaller sized droplets with limited 




Figure 10. Image J analysis of the intensity of Oil Red O staining of rat lungs subjected to different treatments. 




Summary of Findings 
These results extend the evidence of the central involvement of the RAS in the pathology 
of FE and the ability of a direct renin inhibitor, aliskiren, to mitigate this damage. In this study, 
renin inhibition via aliskiren resulted in attenuation of numerous pathologic changes found at 48 
hours post- triolein administration. Some of these changes included (1) reduction in 
inflammation and pulmonary fibrosis as evidenced by the decrease in fibrotic marker expression 
(collagen and α-SMA) in the aliskiren treated animals compared to the triolein only group 
(p<0.01) (2) decreased presence and limited distribution of the fat in aliskiren treated animals 
compared to the triolein only group (p<0.01) which may be related to faster elimination of the 
injected triolein or to intracellular processes related to the RAS, and (3) improvement in vascular 
pathology and vasoconstriction as evidenced by a trend of increased lumen patency.  
Pathophysiology of FE and relation to RAS 
Among many, one of the currently accepted theories of FE maintains a three step 
progression: a mechanical phase begins at the site of insult with intravasation of fat into venous 
circulation and sequestration of this fat in the lung3; a latent phase of apparent resolution; and a 
chemical phase resulting from the action of pulmonary lipase which hydrolyzes the embolized 
neutral fats into more toxic free fatty acids,24, 25, 35 stimulating the release of inflammatory 
mediators. While much remains unknown, it has been demonstrated that many of these 
inflammatory mediators involve the RAS. Gonzalez et al. have suggested the cross-talk between 
pulmonary macrophages and mast cells as playing a key role in the activation of the local RAS.36  
They suggest that, in the presence of hypoxia, an intermediary substance released by alveolar 
macrophages stimulates peripheral mast cell production of renin. 36, 37 Activation of the local 
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RAS ensues leading to the generation of pro-fibrotic Ang II and a general inflammatory 
response. Thus, the presence of fat globlues in the lung may lead to macrophage activation, 
beginning the aforementioned cascade of events.  Further support of this view comes from 
preliminary experiments that demonstrate an increased histochemical expression of angiotensin 
in the lungs22 and renin in the lungs30 and kidneys31 of rats post triolein- induced FE.  
Besides its classical role in blood pressure regulation, it has been previously shown that 
the RAS exerts pro-inflammatory effects, mainly through the action of angiotensin II (Ang II).28 
Ang II, generated by activation of the local RAS, plays a role in tissue repair and remodeling via 
Ang II’s action on transforming growth factor beta (TGF-B), a potent inducer of fibroblast 
procollagen synthesis.38  Through this mechanism, it is believed that Ang II stimulates fibroblast 
procollagen synthesis and promotes lung collagen deposition after lung injury. Ang II has also 
been demonstrated to increase vessel vasoconstriction, vascular permeability,26 and lipase 
expression in vascular tissues39 which would further increase the breakdown of triolein into more 
toxic fatty acids.  
RAS Involvement in Other Models of Pulmonary Fibrosis  
These pro-inflammatory effects of the RAS have been demonstrated to play an important 
role in multiple experimental models pulmonary fibrogenesis beyond FE. The lung 
histopathology found in this study is very similar to that found in other models of pulmonary 
injury and fibrosis where Ang II has been implicated as playing a key role in the pathogenesis. 
Agents interfering with the RAS have been found to abrogate experimental lung injury including 
the prevention of fibrotic, vascular, and bronchial changes induced by a wide variety of insults: 
bleomycin, hypoxia, radiation, monocrotaline, and others.40-48 This protective effect seems to be 
present whether the initial insult is a chemical, physical, or biological stimulus.  
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Potential Protective Properties of Aliskiren  
We previously demonstrated the mitigating effects of captopril and losartan on lung 
histopathology, further elucidating this relationship between RAS and FE pathology.21 In the 
current study, we used aliskiren which also exerts its mechanism of action on the RAS, but 
through direct renin inhibition. It is important to note that, while many RAS-interfering drugs 
have been well studied in the different models of pulmonary fibrosis, there is limited research on 
the effects of aliskiren. To our knowledge, aliskiren has only been employed in two models of 
pulmonary fibrosis,48, 49 neither of which study FE. 
Many properties of aliskiren and its mechanism of action may contribute to its protective 
effects presented in this study. Aliskiren effectively reduces functional plasma renin activity by 
binding to renin with high affinity and preventing it from converting angiotensinogen to Ang I. 
By inhibiting the rate-limiting step of Ang II formation, aliskiren produces more effective and 
complete inhibition of angiotensin II.50 Aliskiren has also been suggested to inhibit local cardiac 
RAS in a rat model51 which may be extrapolated to other local RAS such as pulmonary RAS.  In 
addition, recent studies indicate that aliskiren could be a potent inhibitor of the free forms of 
mature renin and of the receptor-bound forms of renin and prorenin, 52, 53  and therefore aliskiren 
may offer pulmonary protection through its inhibition of both of these mediators.  
There are some possible caveats that may explain aliskiren’s partial, not complete, 
blockade of the triolein-induced histopathologic damage. First, both renin and prorenin maintain 
angiotensin-independent pro-fibrotic properties,54, 55 which are not blocked by aliskiren. Second, 
by inhibiting the production of Ang II, aliskiren also inhibits the production of anti-fibrotic Ang-
(1-7), a breakdown product of Ang II.56 Such implications include the possibility that a higher 
dose of aliskiren may block the protective effect of Ang-(1-7). Lastly, further possibilities 
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include incomplete inhibition of renin by aliskiren and/or the action of chymase or ACE on 
residual Ang I from plasma or tissue sources. However, the results distinctly indicate that renin is 
a major mediator of the RAS in the histopathological effects of FE in the rat. 
Limitations 
One limitation present in our study is the small sample size. The limited number of 
animals may have impacted the results of our vessel measurements including the non-statistically 
significant trend of decreased lumen patency among the triolein-only treated rats which we have 
found significant in multiple past FE studies.4, 20-22 In addition, the optimal dose, timing, and 
route of administration for aliskiren are yet to be defined. The optimal dose may be better 
identified in the future by performing a full dose response curve with aliskiren in these rats. 
Another potential approach is to pre-treat the rats with aliskiren prior to FE-induction to replicate 
clinical prophylactic treatment before certain orthopedic procedures. It is possible that pre-
treatment may demonstrate a more complete blockade of the triolein-induced pathology. Lastly, 
the i.p. dosing of aliskiren selected in this study may complicate future translation into human 
subjects in which the approved route of administration is oral. 
Future Research 
Though there is much evidence authenticating the critical role of the RAS in FE and 
potential therapeutic modalities, many questions remain unanswered. Since other organs 
experience pathologic changes after FE which were protected by losartan,31, 57 the histopathology 
of the hearts and kidneys from these aliskiren-treated animals are currently under investigation. It 
would be desirable to do a dose response curve to determine which dosing regimen (dose, route, 
time) of aliskiren is most appropriate and effective. This study employed post-treatment with 
aliskiren at 1h post-insult to simulate the treatment in a trauma patient; however, pre-treatment 
20 
 
with aliskiren, which may be administered as prophylaxis before certain orthopedic procedures, 
may yield superior results.  In addition, examination at later times beyond 48 hours could 
provide support that this protection blocks both acute and chronic changes observed in FE 
models.   
Based on our current findings, avenues for future studies proposed by our group in rats 
subjected to FE include comparison of mast cell, renin, and prorenin staining amount and 
localization; measuring angiotensin peptides in lung tissue to differentiate angiotensin-
independent effects of renin and prorenin; mast cell depletion or stabilization; macrophage 
depletion or stabilization; and Ang-(1-7) agonists and antagonists. By better defining the role of 
these the individual mediators of the RAS, targeted therapies such as aliskiren can be employed 
to protect the lungs and other organ systems from the resulting acute and chronic damage.   
Clinical Implications  
In summary, aliskiren protected the lungs of these rats from FE-induced pulmonary 
damage at 48 hours. These results provide further confirmation of the relationship between the 
RAS and FE pathology, and that dugs acting on different targets within the RAS may provide 
effective and targeted therapy for FES. Current treatment of FES is limited to supportive therapy 
with mortality figures as high as 20%.1 Since it is suggested that both subclinical FE and clinical 
FES have long term consequences including ARDS, pulmonary fibrosis, and possible 
progression to IPF or COPD, identification of a specific therapy is warranted.  Clinical 
implications include the use of aliskiren or other drugs acting on the RAS both prophylactically 
(before orthopedic procedures) and therapeutically (after severe trauma) for FE to prevent the 
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